Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03547245 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted
A Phase 1 study, sponsored by International AIDS Vaccine Initiative.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT03547245 is a Phase 1 study that has completed, run by International AIDS Vaccine Initiative. The registered enrollment target is 46 participants.
The verdict
NCT03547245, a Phase 1 study, has completed, sponsored by International AIDS Vaccine Initiative.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is a phase 1 first-in-human clinical trial to assess the safety, tolerability, and immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted, in up to 48 healthy adult HIV-negative volunteers.
Interventions
- BIOLOGICAL eOD-GT8 60mer + AS01B/ DPBS sucrose/IM
- BIOLOGICAL DPBS Sucrose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2018-06-15 |
| Est. Completion | 2021-08-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03547245
The ClinicalTrials.gov registry entry for NCT03547245 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International AIDS Vaccine Initiative, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which eOD-GT8 60mer + AS01B/ DPBS sucrose/IM is the first listed.
NCT03547245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03547245 about?
NCT03547245 is a clinical study titled "A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted". This is a phase 1 first-in-human clinical trial to assess the safety, tolerability, and immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted, in up to 48 healthy adult HIV-negative volunteers.
What is the current status of trial NCT03547245?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2018-06-15. Estimated completion is 2021-08-13.
What interventions are being tested in trial NCT03547245?
The interventions under investigation include: eOD-GT8 60mer + AS01B/ DPBS sucrose/IM (BIOLOGICAL), DPBS Sucrose (BIOLOGICAL).
Who is sponsoring clinical trial NCT03547245?
This trial is sponsored by International AIDS Vaccine Initiative, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.